Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder

Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers

(2021) Michael Derks et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder

(2020) Patrick Schnider et al.   JOURNAL OF MEDICINAL CHEMISTRY

Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers

(2020) Michael G. M. Derks et al.   ADVANCES IN THERAPY

Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis

(2020) Spyridon Siafis et al.   Molecular Autism

Environmental and Genetic Factors in Autism Spectrum Disorders: Special Emphasis on Data from Arabian Studies

(2019) Noor Almandil et al.   International Journal of Environmental Research and Public Health

A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism

(2019) Karen J. Parker et al.   Science Translational Medicine

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

(2019) Federico Bolognani et al.   Science Translational Medicine

Clinical trials in autism spectrum disorder

(2018) Evdokia Anagnostou   CURRENT OPINION IN NEUROLOGY

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology

(2017) Oliver D Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

To Screen or Not to Screen Universally for Autism is not the Question: Why the Task Force Got It Wrong

(2016) Karen Pierce et al.   JOURNAL OF PEDIATRICS

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

(2016) Daniel Umbricht et al.   NEUROPSYCHOPHARMACOLOGY

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial

(2016) Jeremy Veenstra-VanderWeele et al.   NEUROPSYCHOPHARMACOLOGY

Systematic review of tools to measure outcomes for young children with autism spectrum disorder

(2015) Helen McConachie et al.   HEALTH TECHNOLOGY ASSESSMENT

Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach

(2015) Hasane Ratni et al.   JOURNAL OF MEDICINAL CHEMISTRY

Baseline Factors Predicting Placebo Response to Treatment in Children and Adolescents With Autism Spectrum Disorders

(2013) Bryan H. King et al.   JAMA Pediatrics

P-640 - The power of expectation bias

(2012) J.B. Williams et al.   EUROPEAN PSYCHIATRY

Neuromodulation by Oxytocin and Vasopressin

(2012) Ron Stoop   NEURON

Gestational Valproate Alters BOLD Activation in Response to Complex Social and Primary Sensory Stimuli

(2012) Ada C. Felix-Ortiz et al.   PLoS One

Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism

(2011) Katherine E Tansey et al.   Molecular Autism

Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder

(2008) Jeffrey A. Bridge et al.   AMERICAN JOURNAL OF PSYCHIATRY